PMID- 25282031
OWN - NLM
STAT- MEDLINE
DCOM- 20151116
LR  - 20151119
IS  - 2213-1787 (Electronic)
IS  - 2213-1779 (Linking)
VI  - 2
IP  - 6
DP  - 2014 Dec
TI  - The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: 
      results from Q-SYMBIO: a randomized double-blind trial.
PG  - 641-9
LID - S2213-1779(14)00336-9 [pii]
LID - 10.1016/j.jchf.2014.06.008 [doi]
AB  - OBJECTIVES: This randomized controlled multicenter trial evaluated coenzyme Q10 
      (CoQ10) as adjunctive treatment in chronic heart failure (HF). BACKGROUND: CoQ10 
      is an essential cofactor for energy production and is also a powerful 
      antioxidant. A low level of myocardial CoQ10 is related to the severity of HF. 
      Previous randomized controlled trials of CoQ10 in HF were underpowered to address 
      major clinical endpoints. METHODS: Patients with moderate to severe HF were 
      randomly assigned in a 2-year prospective trial to either CoQ10 100 mg 3 times 
      daily or placebo, in addition to standard therapy. The primary short-term 
      endpoints at 16 weeks were changes in New York Heart Association (NYHA) 
      functional classification, 6-min walk test, and levels of N-terminal pro-B type 
      natriuretic peptide. The primary long-term endpoint at 2 years was composite 
      major adverse cardiovascular events as determined by a time to first event 
      analysis. RESULTS: A total of 420 patients were enrolled. There were no 
      significant changes in short-term endpoints. The primary long-term endpoint was 
      reached by 15% of the patients in the CoQ10 group versus 26% in the placebo group 
      (hazard ratio: 0.50; 95% confidence interval: 0.32 to 0.80; p = 0.003) by 
      intention-to-treat analysis. The following secondary endpoints were significantly 
      lower in the CoQ10 group compared with the placebo group: cardiovascular 
      mortality (9% vs. 16%, p = 0.026), all-cause mortality (10% vs. 18%, p = 0.018), 
      and incidence of hospital stays for HF (p = 0.033). In addition, a significant 
      improvement of NYHA class was found in the CoQ10 group after 2 years (p = 0.028). 
      CONCLUSIONS: Long-term CoQ10 treatment of patients with chronic HF is safe, 
      improves symptoms, and reduces major adverse cardiovascular events. (Coenzyme Q10 
      as adjunctive treatment of chronic heart failure: a randomised, double-blind, 
      multicentre trial with focus on SYMptoms, BIomarker status [Brain-Natriuretic 
      Peptide (BNP)], and long-term Outcome [hospitalisations/mortality]; 
      ISRCTN94506234).
CI  - Copyright (c) 2014 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Mortensen, Svend A
AU  - Mortensen SA
AD  - Department of Cardiology, Heart Centre, Copenhagen University Hospital, 
      Copenhagen, Denmark. Electronic address: doctormortensen@gmail.com.
FAU - Rosenfeldt, Franklin
AU  - Rosenfeldt F
AD  - Cardiac Surgical Research Unit, Alfred Hospital, Monash University, Melbourne, 
      Australia.
FAU - Kumar, Adarsh
AU  - Kumar A
AD  - Department of Cardiology, Government Medical College/G.N.D. Hospital, Amritsar, 
      India.
FAU - Dolliner, Peter
AU  - Dolliner P
AD  - Department of Internal Medicine II, Medical University of Vienna, Vienna, 
      Austria.
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
AD  - First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
FAU - Pella, Daniel
AU  - Pella D
AD  - Medical Faculty of P.J. Safarik University, Kosice, Slovakia.
FAU - Alehagen, Urban
AU  - Alehagen U
AD  - University Hospital, Linkoping, Sweden.
FAU - Steurer, Gunter
AU  - Steurer G
AD  - Department of Internal Medicine II, Medical University of Vienna, Vienna, 
      Austria.
FAU - Littarru, Gian P
AU  - Littarru GP
AD  - Clinical and Dental Sciences, Biochemistry Section, Polytechnic University of The 
      Marche, Ancona, Italy.
CN  - Q-SYMBIO Study Investigators
LA  - eng
SI  - ISRCTN/ISRCTN94506234
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20141001
PL  - United States
TA  - JACC Heart Fail
JT  - JACC. Heart failure
JID - 101598241
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (Vitamins)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 1339-63-5 (Ubiquinone)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
CIN - JACC Heart Fail. 2014 Dec;2(6):650-2. PMID: 25282030
MH  - Biomarkers/metabolism
MH  - Chronic Disease
MH  - Death, Sudden, Cardiac/etiology
MH  - Double-Blind Method
MH  - Female
MH  - Heart Failure/*drug therapy/mortality
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/metabolism
MH  - Peptide Fragments/metabolism
MH  - Prospective Studies
MH  - Ubiquinone/*analogs & derivatives/therapeutic use
MH  - Vitamins/*therapeutic use
OTO - NOTNLM
OT  - chronic heart failure
OT  - coenzyme Q(10)
OT  - metabolic therapy
OT  - randomized controlled trial
OT  - ubiquinone
EDAT- 2014/10/06 06:00
MHDA- 2015/11/17 06:00
CRDT- 2014/10/06 06:00
PHST- 2014/04/21 00:00 [received]
PHST- 2014/05/31 00:00 [revised]
PHST- 2014/06/13 00:00 [accepted]
PHST- 2014/10/06 06:00 [entrez]
PHST- 2014/10/06 06:00 [pubmed]
PHST- 2015/11/17 06:00 [medline]
AID - S2213-1779(14)00336-9 [pii]
AID - 10.1016/j.jchf.2014.06.008 [doi]
PST - ppublish
SO  - JACC Heart Fail. 2014 Dec;2(6):641-9. doi: 10.1016/j.jchf.2014.06.008. Epub 2014 
      Oct 1.